<DOC>
	<DOCNO>NCT00144053</DOCNO>
	<brief_summary>To evaluate whether two weekly concurrent chemoradiotherapy regimens offer advantage concurrent chemoradiotherapy regimens Cisplatin , Vindesine , Mitomycin unresectable stage III NSCLC .</brief_summary>
	<brief_title>A Phase Ⅲ Randomized Study Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vindesine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<criteria>All patient histologically cytologically confirm locally advanced NSCLC . All patient must undergone previous therapy NSCLC . Patients measurable disease , Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , less 75 year old . Adequate organ ( bone marrow , renal , liver , heart , lung ) function require . All patient give write informed consent . The exclusion criterion consist pulmonary fibrosis , pleural effusion , pregnancy , lactation , active concurrent malignancy , severe drug allergy , myocardial infarction , severe heart disease , uncontrollable diabetes mellitus , infection .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2005</verification_date>
</DOC>